Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 18;6(1):125-129.
doi: 10.1159/000533607. eCollection 2023 Jan-Dec.

Tetrahydrocannabinol in Pediatrics: Room for Improvement?

Charlotte de Gier  1 , Christian Scharinger  2 , Rosa H Stark  2 , Philipp Steurer  3 , Claudia M Klier  3
Affiliations

Tetrahydrocannabinol in Pediatrics: Room for Improvement?

Charlotte de Gier et al. Med Cannabis Cannabinoids. .

Abstract

Introduction: The use of medical cannabis in pediatrics is not common in clinical practice, and there is a lack of prospective studies, especially in pediatric subpopulations. This study aimed to provide data on the off-label administration of tetrahydrocannabinol (∆9-THC) in a pediatric tertiary center in Austria.

Methods: A retrospective data analysis was performed to assess the use of ∆9-THC at the Department of Pediatrics and Adolescent Medicine at the Comprehensive Center of Pediatrics (Medical University Vienna) from 2016 to 2018. The use of ∆9-THC in the Pediatric Department at the Medical University Vienna between 2016 and 2018 was analyzed using a retrospective design.

Results: The most common diagnoses of patients receiving ∆9-THC were brain cancer and genetic diseases, including inborn metabolic disorders. The 32 patients who had received ∆9-THC had an arithmetic mean of 9.42 diagnoses and were treated with an arithmetic mean of 13.52 other drugs. Eleven of the 32 patients died by the end of the study period, indicating palliative use.

Conclusion: The data shows that only severely ill patients were treated with ∆9-THC. A lack of information on the drug's indications, duration, and dosage was noticed in the files, which could represent problems for patient safety.

Keywords: Evaluation; Medical cannabis; Palliative care; Patient safety; Pediatrics; ∆9-tetrahydrocannabinol.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

    1. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462. 10.1124/pr.58.3.2. - DOI - PMC - PubMed
    1. Anderson LL, Absalom NL, Abelev SV, Low IK, Doohan PT, Martin LJ, et al. . Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019 Nov;60(11):2224–34. 10.1111/epi.16355. - DOI - PMC - PubMed
    1. Mosley PE, Webb L, Suraev A, Hingston L, Turnbull T, Foster K, et al. . Tetrahydrocannabinol and cannabidiol in tourette syndrome. NEJM Evid. 2023;2(9):EVIDoa2300012. 10.1056/evidoa2300012. - DOI - PubMed
    1. Berger M, Li E, Rice S, Davey CG, Ratheesh A, Adams S, et al. . Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial. J Clin Psychiatry. 2022 Aug 3;83(5):21m14130. 10.4088/JCP.21m14130. - DOI - PubMed
    1. Mansell H, Quinn D, Kelly LE, Szafron M, Alcorn J. Pharmacokinetics and perceptions of children and young adults using cannabis for attention-deficit/hyperactivity disorder and oppositional defiant disorder: protocol for a mixed methods proof-of-concept study. JMIR Res Protoc. 2021 Oct 18;10(10):e31281. 10.2196/31281. - DOI - PMC - PubMed